<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05092516</url>
  </required_header>
  <id_info>
    <org_study_id>2021P002953</org_study_id>
    <nct_id>NCT05092516</nct_id>
  </id_info>
  <brief_title>Home-based Brain Stimulation Treatment for Post-acute Sequelae of COVID-19 (PASC)</brief_title>
  <official_title>Home-based Transcranial Direct Current Stimulation (tDCS) for Treatment of Cognitive Post-acute Sequelae of COVID-19 (PASC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main goal of this study is to improve dysexecutive symptoms (e.g., sustained attention,&#xD;
      processing speed) in patients exhibiting post-acute sequelae of COVID-19 (PASC) through&#xD;
      home-based transcranial direct current stimulation (tDCS), a noninvasive method that uses low&#xD;
      intensity electric currents delivered to the brain through stimulation electrodes on the&#xD;
      scalp.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2022</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in inhibitory control</measure>
    <time_frame>8 weeks</time_frame>
    <description>Performance during the incongruent trials of the Eriksen Flanker Task will be assessed at four time points before, during, and after the 4-week intervention.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in processing speed</measure>
    <time_frame>8 weeks</time_frame>
    <description>Reaction time during the incongruent trials of the Eriksen Flanker Task will be assessed at four time points before, during, and after the 4-week intervention.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in EEG P300 event-related potential</measure>
    <time_frame>8 weeks</time_frame>
    <description>EEG P300 amplitudes time-locked to the incongruent trials of the Eriksen Flanker Task will be assessed at four time points before, during, and after the 4-week intervention.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Post-Acute Sequelae of COVID-19</condition>
  <arm_group>
    <arm_group_label>Active tDCS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group will receive daily active stimulation (2 mA) to the left dorsolateral prefrontal cortex for 4 weeks through a home-based tDCS device in remotely-supervised 30-min sessions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham tDCS</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>This group will receive daily sham stimulation to the left dorsolateral prefrontal cortex for 4 weeks through a home-based tDCS device in remotely-supervised 30-min sessions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Active tDCS</intervention_name>
    <description>2 mA of anodal stimulation will be applied to the left prefrontal cortex over the F3 electrode based on the International 10-10 EEG system.</description>
    <arm_group_label>Active tDCS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham tDCS</intervention_name>
    <description>Sham stimulation will be applied to the left prefrontal cortex over the F3 electrode.</description>
    <arm_group_label>Sham tDCS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ability to provide informed consent&#xD;
&#xD;
          -  A diagnosis of PASC as indicated by past COVID-19 infection, and persistent symptoms,&#xD;
             including 'brain fog', confusion, short-term memory deficits, trouble concentrating,&#xD;
             delirium, difficulties in multitasking.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of epilepsy&#xD;
&#xD;
          -  Metallic implants in the head and neck,&#xD;
&#xD;
          -  Brain stimulators&#xD;
&#xD;
          -  Pacemakers&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Active substance dependence (except for tobacco)&#xD;
&#xD;
          -  Premorbid major neurological illness&#xD;
&#xD;
          -  Severe mental illness (e.g., bipolar disorder, schizophrenia)&#xD;
&#xD;
          -  ADHD&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hamdi Eryilmaz, Ph.D.</last_name>
    <phone>6176437462</phone>
    <email>hamdi.eryilmaz@mgh.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Blake Andreou, B.S.</last_name>
    <phone>6176438199</phone>
    <email>bandreou@mgh.harvard.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Charlestown</city>
        <state>Massachusetts</state>
        <zip>02129</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Blake Andreou, B.S.</last_name>
      <phone>617-643-8199</phone>
      <email>bandreou@mgh.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Melissa Pax, B.A.</last_name>
      <phone>6177268753</phone>
      <email>mpax@mgh.harvard.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 21, 2021</study_first_submitted>
  <study_first_submitted_qc>October 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2021</study_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Hamdi Eryilmaz, PhD</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Transcranial Direct Current Stimulation</keyword>
  <keyword>EEG</keyword>
  <keyword>Sustained attention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

